Revenue
2022
2023
Unicycive Therapeutics, Inc. (UNCY)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $675,000 | $951,000 | — | — |
| Research & development | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M |
| Operating expenses | $29.5M | $32.1M | $21.4M | $19.0M | $9.0M | $2.0M |
| Operating income | −$29.5M | −$32.1M | −$20.8M | −$18.1M | −$9.0M | −$2.0M |
| EBITDAderived | — | — | — | −$17.6M | −$8.5M | — |
| Net income | −$26.6M | −$36.7M | −$30.5M | −$18.1M | −$10.0M | −$2.3M |
| Basic EPSper diluted share | -$1.67 | -$5.65 | -$1.28 | -$1.20 | -$0.86 | -$0.27 |
| Diluted EPSper diluted share | -$1.67 | -$5.65 | -$1.28 | -$1.20 | -$0.86 | — |